A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

BACKGROUND: Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of type 2 diabetes. It is available in two doses, 0.75 and 1.5 mg, given by injection once weekly. This systematic review reports the effectiveness and safety of dulaglutide in type 2 diabetes in dual and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurung, Tara, Shyangdan, Deepson S, O’Hare, Joseph Paul, Waugh, Norman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541559/
https://www.ncbi.nlm.nih.gov/pubmed/26316788
http://dx.doi.org/10.2147/DMSO.S34418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541559/
https://www.ncbi.nlm.nih.gov/pubmed/26316788
http://dx.doi.org/10.2147/DMSO.S34418

Ejemplares similares